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Background:Meningococcaldisease is adevastating illness that
is endemic to South Africa, where vaccine use is negligible. Disease
incidence typically follows a cyclical pattern. We aim to describe
the epidemiology of invasivemeningococcal disease (IMD) in South
Africa over the past decade.
Methods & Materials: Cases and isolates of IMD were collected
through a national laboratory-based surveillance programme,
GERMS-SA, from January 2003 through December 2012. Demo-
graphic data were collected from all cases and clinical data on
outcome and HIV-status were available from 26 sentinel hospital
sites only. Viable isolates were serogrouped using slide agglutina-
tion to capsular polysaccharides. Incidence rates were calculated
using population denominators from STATS-SA.
Results: Of the 4537 IMD cases reported, 63% (2865) had viable
isolates available for serogrouping and35% (1576) had clinical data.
Seventy-six percent (3461) of cases were identiﬁed from cere-
brospinal ﬂuid, 23% (1052) from blood and 1% (24) from other
invasive specimen types. The majority of cases were sporadic. The
average annual population incidence was 0.9/100 000. Incidence
peakedat1.4/ 100000 in2006anddecreased to0.5/100000 in2012
(p<0.001). Incidencewashighest in infants (8/100000), decreasing
with increased age.Where sexwas known, IMDwasmore common
in males (55%, 2423/4409).
SerogroupsA, B, C,W,Y, X andZall occur in SouthAfrica. In 2003,
serogroupAwas predominant (0.2 /100 000) but numbers declined
steadily and no cases have been reported since 2010. From 2004 to
2012, serogroup W emerged as the predominant serogroup with
a peak in incidence in 2006 at 0.7/100 000. Serogroup B disease is
the secondmost common serogroup and incidence has averaged at
0.13/100 000.
Where patient outcome was known, average case-fatality ratio
(CFR) was 17% (269/1565), however 30% (52/175) of patients
with bacteraemia died versus 16% (217/1380) with meningitis
(p <0.001). HIV-prevalence amongst patients with IMD was 39%
(range 25-48%) - 3.4 times the HIV prevalence (11%) amongst the
general population between 2003 and 2012 (range 10-12%).
Conclusion: Currently IMD in South Africa is at a nadir which
should alert us to the possibility of an increase in disease over the
next few years.
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Otitis media as an infectious disease: the debate
goes on
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Otitis media (OM) has been the subject of prolonged debate
with regard to efﬁcacy of treatment and to the extent of the effect
of pneumococcal conjugate vaccines (PCVs). Much of it is based
on the inability to appropriately diagnose the disease, but even
when studies are designed judiciously, results still do not lead to
unequivocal conclusions. Presently, several highly quoted studies
have clariﬁed some of the issues in regard to response to treat-
ment but the results have generated new questions and debates.
Although evidence showed unequivocally that the great majority
of OM has bacterial infection components, the beneﬁt (both short
and long-term) of antibiotic treatmentwas questionable, while the
association of treatment with adverse events and antibiotic resis-
tance is clear. The effect of PCVs on OM further complicated the
pictureon theonehand, but led to signiﬁcant reduction inburdenof
the other hand. The current understanding of the role of the 2 main
pathogens, S. pneumoniae andnontypeableH. inﬂuenzae (NTHi) and
their interrelationship inOMmake it clear thatwhat is termedbyall
“OM” is in fact a compilation of several entities, each very distinct
bacteriologically and clinically from the other, although part of a
continuum. When looking at each entity separately (acute “sim-
ple” OM; recurrent/non-responsive/spontaneously draining OM;
chronic OM [glue ear] etc.), the explanation of response (or no
response) to treatment and prevention are much clearer. The need
to study each entity separately is emphasized, together with better
deﬁning clinical and research goals.
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